The K8 implant, a first-in-class dual inflammasome inhibitor, demonstrated positive efficacy and safety at 3 months in five patients with bilateral geographic atrophy, according to a press release from Inflammasome Therapeutics.
In the clinical trial, each patient received a single injection of the K8 implant in one eye. As measured by fundus autofluorescence imaging, treated eyes demonstrated a “rapid and substantial reduction of GA lesion growth,” with a mean reduction of 66% at 3 months compared with untreated eyes (P = .029), according to the release. Lesions also progressed at